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Gammaherpesviruses are highly prevalent pathogens that establish 
lifelong latency. However, little is known about how these viruses imprint the 
immune system of their host. Here we used Murid herpesvirus 4 (MuHV-4) to 
investigate the impact of gammaherpesvirus infections on the development of 
an anti-pneumovirus vaccine-induced Th2-skewed immunopathology. Briefly, 
this respiratory hypersensitivity was induced in mice by a subcutaneous 
vaccination with formalin-inactivated antigens of pneumonia virus of mice (FI 
PVM) followed by an intranasal infection with wild-type PVM. We have observed 
that MuHV-4 infection, either before or after the FI PVM vaccination, prevented 
the development of the PVM-induced immunopathology while the protection 
against PVM infection was unaffected. This protective impact against the 
immunopathology was maintained over time and required pulmonary MuHV-4 
replication. Altogether, these results open perspectives for vaccination against 
pneumoviruses and highlight that some so-called pathogens could be revealed 
in the end as beneficial for their host.    
 
 
 
